Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

Information

  • Research Project
  • 8699863
  • ApplicationId
    8699863
  • Core Project Number
    R41AI108029
  • Full Project Number
    1R41AI108029-01A1
  • Serial Number
    108029
  • FOA Number
    PA-10-124
  • Sub Project Id
  • Project Start Date
    4/10/2014 - 11 years ago
  • Project End Date
    3/31/2016 - 9 years ago
  • Program Officer Name
    RITCHIE, ALEC
  • Budget Start Date
    4/10/2014 - 11 years ago
  • Budget End Date
    3/31/2015 - 10 years ago
  • Fiscal Year
    2014
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    4/8/2014 - 11 years ago
Organizations

Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

DESCRIPTION (provided by applicant): Bacterial resistance to ¿-lactam antibiotics is threatening to limit the effectiveness of this most- used class of antibiotics. A major contributin factor to this problem is the lack of rapid testing methods for medical practitioners to identify ¿ lactam-resistant pathogens before prescribing specific antibiotics. For urinary tract infections (UTIs), the most common bacterial infections in the world, older ¿-lactam antibiotics are not used despite the fact that >60% of uropathogens are sensitive to these drugs. Resistance to ¿-lactam antibiotics is conferred by the expression of ¿-lactamases, enzymes that deactivate the antibiotics. We propose the development of a rapid immunoassay test kit for detection of any of a wide range of ¿-lactamases. In Phase I of this project, we aim to develop cross-reactive monoclonal antibodies (MAbs) targeting the homologous regions of the most clinically problematic classes of ¿-lactamases - extended- spectrum -lactamases (ESBLs) and carbapenemases - and then to develop a sandwich ELISA capable of distinguishing -lactam-resistant clinical bacterial isolates from ¿-lactam-sensitive isolates. In Phase II, we will aim to convert this laboratory ELISA into a robust, 10-minute lateral flow immunoassay test kit (similar to the home pregnancy test), capable of detecting ¿-lactamases, and therefore ¿-lactam resistance, directly in patient samples. This capability promises to revolutionize current clinical practice for treatment of (UTIs), allowing the effective use of even the earliest ¿-lactams and preventing the selection of resistance to current first-line treatments.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R41
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    300000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:300000\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SILVER LAKE RESEARCH CORPORATION
  • Organization Department
  • Organization DUNS
    874892821
  • Organization City
    AZUSA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    917023284
  • Organization District
    UNITED STATES